Biosite and FivePrime in diagnostics and therapeutics agreement:
This article was originally published in Clinica
Executive Summary
Biosite has teamed up with fellow California firm Prime Therapeutics to evaluate disease targets for potential diagnostic and therapeutic products. Under the collaboration, FivePrime, which has a comprehensive protein discovery programme, will provide Biosite with access to its selected functional disease targets for use in developing diagnostics. In exchange, FivePrime, of San Francisco, will get access to San Diego-based Biosite's Omniclonal antibodies for selected targets to accelerate its therapeutic research efforts.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.